Brainsway Ltd (BWAY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Brainsway Ltd (BWAY) has a cash flow conversion efficiency ratio of 0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.17 Million) by net assets ($75.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Brainsway Ltd to measure how many days the company can operate on defensive assets alone.
Brainsway Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Brainsway Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Brainsway Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brainsway Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SI-TECH Information Technology Co Ltd
SHE:300608
|
-0.043x |
|
Shenzhen King Explorer Science and Technology Corp Class A
SHE:002917
|
0.035x |
|
Invesco Mortgage Capital Inc
NYSE:IVR
|
0.047x |
|
Happiest Minds Technologies Limited
NSE:HAPPSTMNDS
|
0.018x |
|
ThredUp Inc
NASDAQ:TDUP
|
0.080x |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
-0.005x |
|
NOVA Technology Corporation Limited
SHE:300921
|
N/A |
|
TTY Biopharm Co Ltd
TWO:4105
|
0.097x |
Annual Cash Flow Conversion Efficiency for Brainsway Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Brainsway Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Brainsway Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $73.22 Million | $18.16 Million | 0.248x | +50.10% |
| 2024-12-31 | $62.31 Million | $10.30 Million | 0.165x | +435.19% |
| 2023-12-31 | $41.58 Million | $1.28 Million | 0.031x | +114.36% |
| 2022-12-31 | $45.40 Million | $-9.76 Million | -0.215x | -1494.17% |
| 2021-12-31 | $57.33 Million | $884.00K | 0.015x | +121.08% |
| 2020-12-31 | $19.63 Million | $-1.44 Million | -0.073x | +75.55% |
| 2019-12-31 | $24.22 Million | $-7.24 Million | -0.299x | +44.89% |
| 2018-12-31 | $6.95 Million | $-3.77 Million | -0.543x | -99.13% |
| 2017-12-31 | $12.72 Million | $-3.47 Million | -0.273x | -16.72% |
| 2016-12-31 | $10.29 Million | $-2.40 Million | -0.233x | +33.85% |
| 2015-12-31 | $12.89 Million | $-4.55 Million | -0.353x | -44.97% |
| 2014-12-31 | $15.58 Million | $-3.79 Million | -0.244x | -50.97% |
| 2013-12-31 | $14.65 Million | $-2.36 Million | -0.161x | +77.22% |
| 2012-12-31 | $7.92 Million | $-5.60 Million | -0.708x | -- |
About Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, … Read more